Clinical Trial

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

Study acronym: DurAVR™ EFS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-01-25; most recent amendment 2026-06-25.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-10-18
Trial Details
NCT Number NCT05712161
Lead Sponsor Anteris Technologies Ltd.
Conditions Aortic Stenosis, Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification
Enrollment 15 participants
Start Date 2023-08-07
Primary Completion 2023-12-29 (estimated)
Study Completion 2033-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-26